Home|Journals|Articles by Year Follow on Twitter| Subscribe to List

Directory for Medical Articles
 

Open Access

Short Communication

J App Pharm Sci. 2019; 9(2): 124-128


Qualitative anti-tubercular activity of synthetic ethyl 7-acetyl2-substituted-3-(4-substituted benzoyl) indolizine-1-carboxylate analogues

Sandeep Chandrashekharappa, Katharigatta N. Venugopala, Rashmi Venugopala, Basavaraj Padmashali.

Abstract
The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are currently the major challenges in the treatment of TB. Only delamanid and bedaquiline have been recently approved as anti-TB drugs in the past 40 years. In an attempt to search for active anti-TB compounds against the sensitive strain of Mycobacterium tuberculosis, H37Rv a series of synthetic ethyl 7-acetyl-2-substituted-3-(4-substituted benzoyl)indolizine-1-carboxylates (2a-r) have been screened for in vitro qualitative anti-TB activity using an agar-dilution method. It was found that compounds 2a, 2b 2c, 2f, 2g, 2i, 2j, 2l, 2o, 2p and 2r, which have various functional groups on the indolizine nucleus, were active against the H37Rv strain.

Key words: Indolizine analogues, qualitative screening, agar dilution method, whole cell anti-tubercular screening, H37Rv strain, Mycobacterium tuberculosis.



Share this Article


Advertisement
Journal of Molecular Pathophysiology

SUBMIT YOUR ARTICLE NOW


ScopeMed.com
BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.